Patients with HIV treated by combination antiretroviral therapy (cART) are at risk of developing certain side effects such as reduced response to insulin (this is called insulin resistance), abnormal body fat distribution (HIV lipodystrophy) and high cholesterol levels leading to an increase in the risk of diabetes and heart attacks.

In this study and the sub-study we aim to determine if the use of telmisartan can reduce these side effects.

Please, see patient information sheets for the  Main Study and the Sub-Study for further information

Frequently asked questions

Coming soon!!


I'm fine with this [X]

The site uses cookies, some may have been set already. Please refer to our privacy policy & cookie usage statement.
If you continue to use the site we'll assume you're happy to accept the cookies.